INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death, with incidence and mortality continuing to increase \[[@R1]\]. Although interventional methods for controlling the leading risk factors, hepatitis B virus (HBV) and hepatitis C virus (HCV), have improved, pharmacologically therapeutic and preventive options for HCC still remain limited \[[@R2]\]. Therefore, further development of safe and cost-effective regimens for management of HCC is an urgent need.

Our previous genome-wide association study (GWAS) identified the anti-tumor ligand MHC class I polypeptide-related sequence A (*MICA*) as a susceptibility gene for HCV-induced HCC \[[@R3]\]. Genetic risk of HCC was associated with MICA expression in chronic hepatitis C patients \[[@R4], [@R5]\] as well as patients with HBV infection \[[@R6]\], thereby indicating hypofunction of anti-HCC immunity by MICA insufficiency as a therapeutic target \[[@R7]\]. In line with this hypothesis, restoration of membrane-bound MICA (mMICA) levels in HCC cells augmented natural killer (NK) cell-mediated anti-cancer activity in our and other groups' studies \[[@R2], [@R7]\], proving the concept of natural killer group 2D (NKG2D) signaling-mediated immunotherapy. We also demonstrated significant mMICA upregulation and reduction of levels of soluble MICA (sMICA), an immunological decoy, by an inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) \[[@R2]\]. ADAM10 is reported to be a MICA sheddase \[[@R8]\] and a promoter of HCC cell proliferation, invasion, and migration, which is correlated with worse prognosis and shorter survival in patients \[[@R9]\]. Hence, we aimed to develop molecular pharmacological regulation of ADAM10 enzyme activity to modulate mMICA expression and have potential chemotherapeutic effects. We explored approved drugs, using a newly established *in vitro* assay system. Interestingly, a long-used anti-alcoholism drug, disulfiram (DSF), was identified and its cellular action was investigated.

RESULTS {#s2}
=======

DSF inhibits ADAM10 activity *in vitro* {#s2_1}
---------------------------------------

To evaluate the enzymatic activity of ADAM10, we established a new *in vitro* assay system. Recombinant human ADAM10 (rhADAM10) protein was incubated with a fluorescent peptide substrate for fluorescence resonance energy transfer (FRET) analysis, as described in the Materials and Methods. RhADAM10-specific fluorescence was observed. Marimastat (MMS), an ADAM10 inhibitor \[[@R10]\], suppressed fluorescence in a dose-dependent manner (Figure [1A](#F1){ref-type="fig"}), validating the reporter system. We subsequently tested 636 FDA-approved drugs *in vitro*; six drugs demonstrated inhibitory effects of more than 80% in the primary screen, and an anti-alcoholism drug, DSF, was the top hit (Figure [1B](#F1){ref-type="fig"}).

![Inhibitory effects of DSF on ADAM10 *in vitro*\
**(A)** The *in vitro* ADAM10 enzyme assay system was validated using the known inhibitor MMS as a positive control. **(B)** The effects of 636 compounds in the FDA-Approved Drug Screen-well Library were tested *in vitro*. **(C)** The chemical structures of DSF and its analogues and metabolites, retrieved from the database ChemSpider. *In vitro* effects of **(D)** DSF, TR and TMTM at 0.5, 1, and 10 μM, and **(E)** DDC, DETC-MeSO and DDTC-MeSO at 1 and 10 μM.](oncotarget-09-18821-g001){#F1}

Then we investigated the inhibitory action of DSF (Figure [1C](#F1){ref-type="fig"}) in detail. DSF moderately suppressed ADAM10 activity in a dose-dependent manner at dosages below clinical concentrations (Figure [1D](#F1){ref-type="fig"}), replicating the results of the primary screen. Next, to identify the functional groups of DSF responsible for the inhibitory activity, two close analogues of DSF, tetramethylthiuram disulfide (TR) and tetramethylthiuram monosulfide (TMTM), were investigated (Figure [1C](#F1){ref-type="fig"}). TR exhibited inhibitory effects but TMTM did not (Figure [1D](#F1){ref-type="fig"}), indicating the importance of the disulfide bond. DSF metabolites diethyldithiocarbamate (DDC), S-methyl-N,N-diethylthiocarbamoyl sulfoxide (DETC-MeSO), and S-methyl-N,N-diethyldithiocarbamate-sulfoxide (DDTC-MeSO) (Figure [1C](#F1){ref-type="fig"}) were also tested, and at the effective doses of DSF and TR, no inhibition was observed (Figure [1E](#F1){ref-type="fig"}). Thus, the disulfide bond-based conformational integrity is suggested to be important for the inhibition of ADAM10 activity by DSF.

DSF suppresses sMICA production and selectively upregulates mMICA {#s2_2}
-----------------------------------------------------------------

We examined the effects of DSF on MICA expression in HCC cells. PLC/PRF/5 cells were treated with DSF or the analogues for 48 h, and then cell viability was tested and culture supernatants were collected for ELISA. At noncytotoxic doses, DSF (Figure [2A](#F2){ref-type="fig"}) and TR (Figure [2B](#F2){ref-type="fig"}) suppressed the relative sMICA level but TMTM (Figure [2C](#F2){ref-type="fig"}) and DDC (Figure [2D](#F2){ref-type="fig"}) did not, and the inhibitory effect of DSF was abrogated ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}) by the knockdown of ADAM10 ([Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}). Conversely, mMICA levels in PLC/PRF/5 cells treated for 72 h were increased by DSF and TR in a dose-dependent manner, but not by TMTM and DDC (Figure [2E](#F2){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}); the stimulatory effects of DSF on mMICA were also observed in additional hepatoma cell lines, Li7 and HLE ([Supplementary Figure 1C](#SD1){ref-type="supplementary-material"}). Concomitantly, NK cell-mediated cytotoxicity to DSF-treated PLC/PRF/5 cells was potentiated in coculture ([Supplementary Figure 1D](#SD1){ref-type="supplementary-material"}). Therefore, DSF was suggested to enhance mMICA levels and suppress sMICA production with enzymatic inhibition of ADAM10, leading to anti-cancer activity of NK cells. To confirm that ADAM10 activity is specifically targeted by DSF, we evaluated the effects of DSF on transcription of *MICA* and *ADAM10*. DSF (Figure [2F](#F2){ref-type="fig"}) and TR (Figure [2G](#F2){ref-type="fig"}), as well as TMTM and DDC (Figure [2H](#F2){ref-type="fig"} and [2I](#F2){ref-type="fig"}), did not significantly affect *MICA* mRNA levels. TR alone exhibited a moderate suppression of *ADAM10* mRNA levels (Figure [2G](#F2){ref-type="fig"}) while DSF (Figure [2F](#F2){ref-type="fig"}) and the other compounds (Figure [2H](#F2){ref-type="fig"} and [2I](#F2){ref-type="fig"}) had no effect.

![DSF reduces sMICA production and enhances mMICA levels\
After the treatment of PLC/PRF/5 cells for 48 h, the effects of **(A)** DSF, **(B)** TR, **(C)** TMTM, and **(D)** DDC on sMICA production and cell viability were examined. ^\*^*P* \< 0.05 by the Welch t-test. **(E)** After the treatment of PLC/PRF/5 cells for 72 h, the effects of DSF (0, 5, and 15 μM in blue, purple, and red, respectively), TR (0, 5, and 15 μM in blue, purple, and red, respectively), TMTM (0 and 15 μM in blue and red, respectively), and DDC (0 and 15 μM in blue and red, respectively) on mMICA levels were evaluated flow cytometrically, with the isotype controls displayed as gray histograms. After the treatment of PLC/PRF/5 cells for 48 h, the effects of **(F)** DSF, **(G)** TR, **(H)** TMTM, and **(I)** DDC on relative mRNA levels of *MICA*, *ADAM9*, and *ADAM10* were determined by qRT-PCR with normalization to *GAPDH*. **(J)** Effects of DSF at 0.5, 1, and 10 μM and ILM at 1 μM on ADAM9 were tested *in vitro*.](oncotarget-09-18821-g002){#F2}

ADAM9 has also been reported to be a MICA sheddase in HCC cells \[[@R11]\], and suppression of ADAM9 by DSF was investigated simultaneously. Similar to that for ADAM10, an *in vitro* ADAM9 FRET assay system was developed, as described in the Materials and Methods; an ADAM9 inhibitor, ilomastat (ILM) \[[@R12]\], suppressed ADAM9 activity while DSF did not (Figure [2J](#F2){ref-type="fig"}). *ADAM9* mRNA levels were not altered by DSF (Figure [2F](#F2){ref-type="fig"}), TR (Figure [2G](#F2){ref-type="fig"}), TMTM, or DDC (Figure [2H](#F2){ref-type="fig"} and [2I](#F2){ref-type="fig"}). These results indicate that ADAM9 is not targeted either transcriptionally or enzymatically by DSF.

To investigate potentially unfavorable immunological effects of DSF, we tested its influence on NK cells. In cells from a NK cell line (NK92MI) treated with DSF for 48 h, *NKG2D* mRNA levels were intermediately decreased (Figure [3A](#F3){ref-type="fig"}) but its cell surface protein level was not altered (Figure [3B](#F3){ref-type="fig"}). Cell viability was significantly reduced at higher doses (Figure [3A](#F3){ref-type="fig"}). At 5 μM, an effective dose for ADAM10 inhibition, DSF was indicated to function without disturbance of the NKG2D signaling and NK cells.

![Effects of DSF on NK cells and normal human hepatocytes\
After the treatment of NK92MI cells for 48 h, **(A)** the effects of DSF at 5, 10, and 15 μM on relative *NKG2D* mRNA levels were examined by qRT-PCR with normalization to *GAPDH*, and **(B)** the effects of DSF (0 and 5 μM in blue and red, respectively, with the isotype control displayed as a gray histogram) on cell surface protein expression of NKG2D was examined by flow cytometry; simultaneously, (A) the effects of DSF at the indicated doses on cell viability was monitored. After the treatment of PXB cells for 48 h, effects of **(C)** DSF, **(D)** TR, **(E)** TMTM, and **(F)** DDC were examined by qRT-PCR with normalization to *GAPDH*.](oncotarget-09-18821-g003){#F3}

We also examined the impact of DSF on normal human hepatocytes. In PXB cells from chimeric mice with a humanized liver \[[@R13]\] treated for 48 h, neither DSF (Figure [3C](#F3){ref-type="fig"}), TR (Figure [3D](#F3){ref-type="fig"}), TMTM, nor DDC (Figure [3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}), at the noncytotoxic dose \[[@R14]\], altered the mRNA levels of *MICA*, *ADAM9*, or *ADAM10*. This confirms that DSF is free from unwanted induction of the immunoactivating ligand on normal hepatocytes, which would specifically increase mMICA levels with ADAM10 enzyme inhibition.

Mechanism of ADAM10 inhibition by DSF in a combination treatment {#s2_3}
----------------------------------------------------------------

To investigate the mechanism of ADAM10 inhibition by DSF, we performed an *in vitro* combination assay with a well-known zinc-binding probe, acetohydroxamic acid (AHA) \[[@R10]\]. The dose-dependent inhibition of ADAM10 activity by DSF was further reinforced in the presence of AHA (Figure [4A](#F4){ref-type="fig"}). All calculated combination indices (CIs) were less than 1.0 (Figure [4B](#F4){ref-type="fig"}), indicating synergistic effects \[[@R10]\] of combining DSF and AHA. This result was also supported by the analysis of normalized isobologram (Figure [4C](#F4){ref-type="fig"}). The data at least indicates a mode of non-zinc-binding inhibition of ADAM10 by DSF, as DSF and AHA did not compete with each other \[[@R10]\].

![Combination treatment with DSF and AHA\
Effects of the combination treatment with DSF and AHA on ADAM10 **(A)** were tested *in vitro*, and synergism was evaluated by **(B)** CI and **(C)** normalized isobologram at the following ratios: 1) 0.5:1, 2) 0.5:2, 3) 1:1, 4) 1:2, 5) 10:1, and 6) 10:2 (DSF (μM):AHA (mM)). After the treatment of PLC/PRF/5 cells with DSF and AHA at the indicated doses for 48 h, **(D)** relative cell viability and **(E)** sMICA levels were measured. ^\*^*P* \< 0.05 by the Welch t-test. **(F)** The mMICA levels in PLC/PRF/5 cells were examined by flow cytometry after no treatment (Blue), monotreatment with DSF (purple) or AHA (red), and cotreatment with DSF and AHA (green) for 72 h, with the isotype control displayed as a gray histogram. After cotreatment with DSF and AHA at the indicated doses for 48 h, relative mRNA levels of *MICA* **(G)**, *ADAM9* **(H)**, and *ADAM10* **(I)** were measured by qRT-PCR with normalization to *GAPDH*.](oncotarget-09-18821-g004){#F4}

On the basis of the moderate inhibition of ADAM10 by AHA (Figure [4A](#F4){ref-type="fig"}), in addition, we investigated the effects of AHA on HCC cells by methods similar to those used to evaluate DSF. As expected, AHA modestly decreased viabilities of PLC/PRF/5 cells after a 48-h treatment, which was more pronounced when applied in combination with DSF (Figure [4D](#F4){ref-type="fig"}). Interestingly, AHA elevated sMICA levels in PLC/PRF/5 cells after a 48-h treatment, in contrast to the downregulation induced by DSF (Figure [4E](#F4){ref-type="fig"}). This indicates that AHA is an inducer of MICA expression. Flow cytometric analysis of the cells treated with AHA for 72 h predictably demonstrated the enhancement of mMICA levels, and this was slightly reinforced by DSF (Figure [4F](#F4){ref-type="fig"}). The same pattern was found for *MICA* mRNA levels as well (Figure [4G](#F4){ref-type="fig"}), but the expression of *ADAM9* (Figure [4H](#F4){ref-type="fig"}) and *ADAM10* (Figure [4I](#F4){ref-type="fig"}) was not affected by AHA, with or without DSF. Thus, the potential utility of AHA, an approved urease inhibitor Lithostat, for mMICA upregulation and HCC cell suppression was also found during this combination assay.

DSF possesses anti-migratory activity {#s2_4}
-------------------------------------

Since ADAM10 is notorious for the ability to promote migration of HCC cells \[[@R9], [@R15]\], we also tested anti-migratory effects of DSF. Wound closure assays demonstrated that DSF exerted inhibitory effects on PLC/PRF/5 cell proliferation and migration (Figure [5A](#F5){ref-type="fig"}). The assays were subsequently performed after pretreatment with mitomycin, and the anti-migratory effects of DSF were still observed, slightly increased by AHA, a reported migration inhibitor (Figure [5B](#F5){ref-type="fig"}); the inhibitory effects of DSF were observed in additional hepatoma cell lines, Li7 and HLE, as well ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). TR also showed effects (Figure [5C](#F5){ref-type="fig"}) while TMTM (Figure [5D](#F5){ref-type="fig"}) and DDC (Figure [5E](#F5){ref-type="fig"}) did not. DSF was therefore suggested to possess anti-migratory activity in relation to ADAM10 inhibition, as the effects were associated with *in vitro* inhibitory activity.

![Wound closure assay\
**(A)** PLC/PRF/5 cells were treated with DSF for 24 h. PLC/PRF/5 cells were pretreated with mitomycin at 10 μg/mL for 1 h, followed by treatment with DSF and/or **(B)** AHA, **(C)** TR, **(D)** TMTM and **(E)** DDC at the indicated doses for 48 h. Relative wound sizes to the controls are indicated individually; dashes denote no detection of wounds.](oncotarget-09-18821-g005){#F5}

DISCUSSION {#s3}
==========

Our preclinical proof-of-concept study \[[@R2]\] based on the previous GWAS \[[@R3]\] suggested the anti-HCC immunotherapeutic validity of targeting ADAM10 to increase mMICA expression. Besides the discovery and observation of inhibitory effects of DSF on ADAM10 activity, pleiotropy of the enzyme was reflected in the various chemotherapeutic properties of DSF. Novel and multiple effective chemoimmunotherapeutic strategies can be considered based on the unique properties of DSF and ADAM10 (Figure [6](#F6){ref-type="fig"}).

![Therapeutic modes of DSF targeting ADAM10\
DSF has been increasingly recognized to possess anti-cancer effects through various pathways (orange). Here, DSF was discovered to exert inhibitory effects on the enzymatic activity of ADAM10 (purple), which promotes MICA shedding, enhances sMICA production and decreases mMICA level, and suppresses anti-HCC activity of NK cells (red, immunotherapeutic targets). ADAM10 also promotes HCC cell proliferation and migration (blue, chemotherapeutic targets).](oncotarget-09-18821-g006){#F6}

Following reports in several cancer cell lines \[[@R16]\], ADAM10 was also found to be overexpressed and to shed mMICA in HCC cells \[[@R8]\]. Pharmacological modulation of ADAM10 has proven to be effective. Both transcriptional downregulation \[[@R8]\] and enzymatic inhibition of ADAM10 \[[@R2]\] enhanced mMICA levels and reduced sMICA production in HCC cells, leading to the augmentation of NK cell-mediated cytotoxicity. Additionally, DSF did not upregulate *MICA* expression in normal human hepatocytes, with very low protein levels of MICA and ADAM10 in contrast to HCC cells \[[@R8], [@R17], [@R18]\], or interfere with *NKG2D* expression in NK cells (Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}), which indicated selective enhancement of mMICA levels in HCC cells and efficient transduction of signaling for NK cell activation. Therefore, DSF is expected to possess immunotherapeutic properties without unfavorable off-target effects.

Mechanistically, possible non-zinc-binding inhibition was indicated from analysis of ADAM10 inhibition by DSF, implying that coadministration of DSF with chelating drugs could be an attractive strategy. Furthermore, AHA significantly elevated MICA expression levels; through zinc-binding properties, hydroxamic acids are known to inhibit enzymatic activities of zinc-metalloproteins such as Matrix Metallo Proteinase (MMP) and histone deacetylases (HDACs) \[[@R19]\]. In our recent study, HDAC inhibitor (HDACi) suberoylanilide hydroxamic acid, also known as vorinostat (VOR), strongly enhanced MICA expression, potentiating NK cell-mediated anti-HCC activity in cell culture and *in vivo* \[[@R2]\]. Here, the pronounced induction of mMICA levels by AHA, supposedly due to ADAM10 inhibition and whether or not HDACs are inhibited as well, is of practical use and of interest for further mechanistic investigation. Accordingly, development and utilization of hydroxamic acids dually targeting ADAM10 and HDACs, as implied by molecules against MMPs and HDACs \[[@R20]\], is warranted. Thus, therapeutic methods using DSF, DSF analogues/derivatives, or better potent ADAM10 inhibitors and hydroxamic acids could achieve potent immunotherapeutic effects by robust elevation of mMICA levels and *MICA* transcription, as well as selective inhibition of MICA shedding; importance of strategic surveillance and management of sMICA was learned as well from a series of clinicogenetic studies \[[@R3], [@R5], [@R6]\].

Meanwhile, ADAM10 has been recognized to promote cell migration in multiple cancers \[[@R21]\] including HCC \[[@R9], [@R15]\], and so inhibition of ADAM10 has been demonstrated to have anti-migratory effects. In this study, HCC cell migration was suppressed by DSF and TR, as well as AHA, but not by TMTM and DDC (Figure [5](#F5){ref-type="fig"}), supporting the validity of ADAM10 enzyme inhibition protecting against HCC progression. Considering that DSF suppresses migratory properties of various cancer types through targets other than ADAM10 \[[@R22]\], it can be an even more attractive agent.

ADAM10 is also known to promote cell growth in HCC \[[@R9], [@R15]\] and other cancers \[[@R21]\]. We recently showed inhibitory effects of DSF and TR on HCC cell proliferation \[[@R14]\], and in the current study, AHA exerted anti-HCC effects as well (Figure [4D](#F4){ref-type="fig"}). This strengthens the concept of inhibiting ADAM10 in order to suppress HCC. DSF is also capable of exerting effects targeting many diverse molecules \[[@R23]\], as represented by apoptosis induction through the reactive oxygen species-p38 pathway \[[@R24]\]. Our analyses demonstrated that DDC, a DSF metabolite shown to lack inhibitory effects on ADAM10 enzyme activity (Figure [1E](#F1){ref-type="fig"}), also decreased HCC cell viability \[[@R14]\], suggesting a further potential effect of DSF against HCC.

Thanks to such chemotherapeutic features against cancer cell proliferation and migration as discussed above and recently proved even in a nationwide epidemiological study of Danish patients with cancer \[[@R25]\], the anti-cancer properties of DSF are becoming increasingly appreciated ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) and tested in clinical trials across cancer types \[[@R23]\]. Our data describing ADAM10 inhibition has uncovered another aspect of DSF as an anti-cancer agent. At relatively lower doses, DSF suppressed MICA shedding (Figure [2](#F2){ref-type="fig"}), and cytotoxicity was not observed until higher doses were applied \[[@R14]\], indicating the drug action gradually switched from immunotherapeutic to chemotherapeutic modes. The therapeutic activities of DSF were HCC-cell selective, as was seen in the inhibition of MICA shedding (Figure [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}) and cell growth \[[@R14]\], and this dual action is thought to be safely effectuated. Besides, the induction of MICA expression and inhibition of HCC cell viability by AHA were of particular interest as the compound is an approved urease inhibitor Lithostat. The enhanced effects of DSF in the presence of AHA suggest chemotherapeutic potential of a DSF-based regimen with the addition of approved drugs capable of inducing mMICA expression and inhibiting HCC cell proliferation, such as VOR \[[@R2]\]. This is expected to accelerate implementation of practical treatment options using available clinical agents.

Following a breakthrough in cancer immunotherapy \[[@R26]\] and continuous development of new molecularly targeted therapies \[[@R27]\], combined therapies are drawing more attention \[[@R28]\]. Recently, significant and synergistic suppression of tumor growth by the combination of anti-programmed cell death protein 1 antibodies and an FDA-approved receptor tyrosine kinase inhibitor, sunitinib, in a murine model of human HCC was reported \[[@R29]\]. The SHELTER study also exhibited a high disease control rate in HCC patients treated by an HDACi, resminostat, and sorafenib \[[@R30]\], capable of inducing *MICA* expression \[[@R2]\] and suppressing ADAM9-mediated mMICA shedding \[[@R11]\], respectively, suggesting chemoimmunotherapeutic effects \[[@R31]\]. Similarly, DSF, which has been indicated to possess both chemotherapeutic and immunotherapeutic properties, and/or its analogues may be used as treatments. The data in this study would lead to the development of new, safe, and cost-effective anti-HCC regimens.

MATERIALS AND METHODS {#s4}
=====================

Compounds and cells {#s4_1}
-------------------

DSF was purchased from Selleckchem (Houston, TX, USA). TR, TMTM, Sodium diethyldithiocarbamate trihydrate, and MMS were purchased from Sigma-Aldrich (St. Louis, MO, USA). AHA and mitomycin were purchased from Wako Pure Chemical Industries (Osaka, Japan). ILM was purchased from Focus Biomolecules (Plymouth Meeting, PA, USA). DETC-MeSO and DDTC-MeSO were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The FDA-Approved Drug Screen-well Library and Cell Counting Kit (CCK)-8 were obtained from Enzo Life Sciences (Farmingdale, NY, USA) and Dojindo (Kumamoto, Japan), respectively. PLC/PRF/5 cells were authenticated by the short tandem repeat method (Bex, Tokyo, Japan) in 2016 and cultured in Dulbecco's modified Eagle medium containing fetal bovine serum according to the protocol ([www.atcc.org/Products/All/CRL-8024.aspx\#culturemethod](www.atcc.org/Products/All/CRL-8024.aspx#culturemethod)) of American Type Culture Collection (ATCC) (Manassas, VA, USA). NK92MI cells were also obtained from ATCC and cultured in Alpha Minimum Essential medium containing horse and fetal bovine serums following the protocol ([www.atcc.org/Products/All/CRL-2408.aspx\#culturemethod](www.atcc.org/Products/All/CRL-2408.aspx#culturemethod)). PXB cells were purchased from Phoenix Bio (Hiroshima, Japan). Cells were cultured at 37°C and 5 % CO~2~.

*In vitro* ADAM assay {#s4_2}
---------------------

RhADAM9 (R&D systems, Minneapolis, MN) was incubated with a fluorescent peptide substrate (BioZyme, Apex, NC, USA), at 20 μg/mL and 10 μM, respectively, in the presence of DMSO or a compound according to the manufacturer's instructions. After reacting for 24 h at 37°C, fluorescent signals were measured, and relative enzymatic activities were calculated. RhADAM10 (R&D systems) was incubated with a fluorescent peptide substrate (BioZyme), at 0.5 μg/mL and 10 μM, respectively, in the presence of DMSO or a compound according to the manufacturer's instructions. After reacting for 2 h at 37°C, fluorescent signals were measured, and relative enzymatic activities were calculated.

Analysis of drug combinations {#s4_3}
-----------------------------

Synergism between DSF and AHA was calculated using CalcuSyn software (Biosoft, Ferguson, MO, USA) based on the method of Chou and Talalay \[[@R32]\] as described previously \[[@R33]\].

Quantitative reverse transcription-polymerase chain reaction {#s4_4}
------------------------------------------------------------

Relative mRNA levels were quantified as previously described \[[@R34]\], using the following primer sets: MICA-F 5\'-CTTCCTGCTTCTGGCTGGCATC-3\' and MICA-R 5\'- CAGGGTCATCCTGAGGTCCTTTC-3\' for *MICA*, ADAM9-F 5\'-TCCATTGCTCTTAGCGACTGT-3\' and ADAM9-R 5\'-GGGGTTCAATCCCATAACTCG-3\' for *ADAM9*, ADAM10-F 5\'-ATGGGAGGTCAGTATGGGAATC-3\' and ADAM10-R 5\'-ACTGCTCTTTTGGCACGCT-3\' for *ADAM10*, NKG2D-F 5\'-GAGTGATTTTTCAACACGATGGC-3\' and NKG2D-R 5\'-ACAGTAACTTTCGGTCAAGGGAA-3\' for *NKG2D*, and GAPDH-F2 5\'-AAGGTGAAGGTCGGAGTCAAC-3\' and GAPDH-R2 5\'-GGGGTCATTGATGGCAACAATA-3\' for glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), with the values of *MICA*, *ADAM9*, *ADAM10*, and *NKG2D* normalized to that of *GAPDH*.

Flow cytometry {#s4_5}
--------------

Flow cytometry was performed as described previously \[[@R2]\], using the following antibodies (R&D Systems) according to the manufacturer's protocol: Alexa 488-conjugated mouse IgG isotype control, human MICA, or human NKG2D antibody.

ELISA {#s4_6}
-----

ELISA was performed as described previously \[[@R2]\] using MICA ELISA Kit (Diaclone, Besançon, France) according to the manufacturer's protocol.

Wound closure assay {#s4_7}
-------------------

Using Culture-Insert (Ibidi, Martinsried, Germany), the procedure was performed according to the manufacturer's protocol. Briefly, 70 μL of PLC/PRF/5 cell suspension at 8 × 10^5^ cells/mL was applied into each well, and 24 h later the Culture-Insert was removed. After the pretreatment with mitomycin at 10 μg/mL for 1 h, cells were incubated in the presence of compounds for 48 h. Wound areas were measured by Image J (NIH, Bethesda, MD, USA).

Statistical analysis {#s4_8}
--------------------

The bar graphs of the *in vitro* ADAM10 assay, ELISA, cell viability assay, and qRT-PCR are presented as means ± SD. A Welch t-test was performed for statistical analysis of ELISA results.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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